Evidence map›Paper›PMID 28025742›Full record

ArticlePsychopharmacology2017

Loss-of-function of PTPR γ and ζ, observed in sporadic schizophrenia, causes brain region-specific deregulation of monoamine levels and altered behavior in mice.

Arnaud Cressant, Veronique Dubreuil, Jing Kong, Thorsten Manfred Kranz, Francoise Lazarini, Jean-Marie Launay, Jacques Callebert, Jan Sap, Dolores Malaspina, Sylvie Granon and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Tail-rattling in rodents: more than a threat display.Journal of comparative physiology. A, Neuroethology, sensory, neural, and behavioral physiology · 2026
    Review
  2. Article
  3. Phosphatase Signaling as a Therapeutic Strategy in Schizophrenia.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. World journal of psychiatry · 2022
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Arnaud CressantNeurobiologie de la prise de décision, Paris-Saclay Institute of Neuroscience (Neuro-PSI), CNRS UMR 9197 and Université Paris Sud, Orsay, France.
Veronique DubreuilDepartment of Neuroscience, Institut Pasteur, 75724, Paris, France.
Jing KongDepartment of Neuroscience, Institut Pasteur, 75724, Paris, France.
Thorsten Manfred KranzDepartment of psychiatry, New York University Langone School of Medicine, New York, NY, 10016, USA.
Francoise LazariniInstitut Pasteur, URA 2182, 75015, Paris, France.
Jean-Marie LaunayLaboratoire de Biochimie et Biologie Moléculaire Hôpital Lariboisière, INSERM U942, 75010, Paris, France.
Jacques CallebertLaboratoire de Biochimie et Biologie Moléculaire Hôpital Lariboisière, INSERM U942, 75010, Paris, France.
Jan SapUniversité Paris 7 Diderot, Sorbonne Paris Cité, Paris, France.
Dolores MalaspinaDepartment of psychiatry, New York University Langone School of Medicine, New York, NY, 10016, USA.
Sylvie GranonNeurobiologie de la prise de décision, Paris-Saclay Institute of Neuroscience (Neuro-PSI), CNRS UMR 9197 and Université Paris Sud, Orsay, France.
Sheila HarrochDepartment of Neuroscience, Institut Pasteur, 75724, Paris, France. Harrochsheila@gmail.com.
NYU Langone Health · USInserm · FRInstitut Pasteur · FRUniversité Paris-Sud · FRDélégation Paris 7 · FRSorbonne Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleThe receptor protein tyrosine phosphatase PTPRG has been genetically associated with psychiatric disorders and is a ligand for members of the contactin family, which are themselves linked to autism spectrum disorders.

objectiveBased on our finding of a phosphatase-null de novo mutation in PTPRG associated with a case of sporadic schizophrenia, we used PTPRG knockout (KO) mice to model the effect of a loss-of-function mutation. We compared the results with loss-of-function in its close paralogue PTPRZ, previously associated with schizophrenia. We tested PTPRG

resultsThe most notable behavioral consequences of PTPRG gene inactivation were reduced immobilization in the forced swim test, suggestive of some negative symptoms of schizophrenia. By contrast, PTPRZ

conclusionPTPRG and PTPRZ gene loss therefore induces distinct patterns of behavioral change and region-specific alterations in neurotransmitters, highlighting their usefulness as models for neuropsychiatric disorder mechanisms and making these receptors attractive targets for therapy.

Indexed as

Social BehaviorAmygdalaAnimalsCorpus StriatumDopamineHippocampusMaleMiceMice, KnockoutReceptor-Like Protein Tyrosine Phosphatases, Class 5SchizophreniaSerotoninSwimmingDopaminePtprg protein, mousePtprz1 protein, mouseReceptor-Like Protein Tyrosine Phosphatases, Class 5SerotoninAggressionAnxietyContactinsMental disordersPhosphataseSocial behavior

Identifiers

PMID28025742
OpenAlexW2562667380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.